BeStock  
Stocks › Biotechnology › RXRX

Recursion Pharmaceuticals RXRX

US equityMarket cap rank #2863BiotechnologyAI medical concept stocks
$2.45 −$0.27 (-9.93%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $2.51 +2.39%
Open$2.63
Prev close$2.72
Day range$2.44 – $2.76
Volume29.88M
Market cap$1.53B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership62.7%-10.09 pts vs. prior quarter
Institutions holding382-10 vs. prior quarter
Insider trades (recent)10 buys / 40 sellsNet selling
ARK fund activity+4,230,235 sh1 recent transactions · last 14 Oct 2026
Short interest23.80% of floatDays to cover 6.1 · as of 30 Oct 2026
Short-sale volume share19.7%5-day average of daily volume

Short-sale volume as % of daily volume

9%18%26%35%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$11.11M (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

−$2.9MSuper−$8.2MBig−$8.8MMid−$16.5MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 30.0% of shares outstanding.

Largest holders

  • BlackRock8.58%
  • ARK Investment Management LLC7.18%
  • Vanguard Portfolio Management, LLC5.74%
  • State Street Global Advisors4.81%
  • Vanguard Capital Management, LLC3.69%
  • Baillie Gifford2.92%
  • Geode Capital Management, LLC2.23%
  • SoftBank Group Corp.2.19%

By investor type

  • Mutual Fund49.20%
  • Public Company4.46%
  • VC/PE Fund3.95%
  • Individual/Insider2.55%
  • Hedge Fund2.52%
  • Sovereign Wealth Fund1.10%
  • Private Company0.93%
  • Insurance Company0.27%

Reported short interest has fallen from 33.24% to 23.80% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
GWL Investment Management Ltd. Mutual Fund 2026/Q3 +4,779,708 1.3%
FMR Mutual Fund 2026/Q3 +11,390,097 1.8%
GWL Investment Management Ltd. Mutual Fund 2026/Q3 +4,832,512 1.4%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +4,680,546 5.7%
Morgan Stanley Public Company 2026/Q3 +3,481,256 1.0%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +3,481,256 1.0%
ARK Investment Management LLC Mutual Fund 2026/Q3 +3,407,393 7.2%
BlackRock Mutual Fund 2026/Q3 +3,174,188 8.6%
MFS Investment Management Mutual Fund 2026/Q3 +2,391,009 0.4%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +1,525,733 0.2%
Creative Planning, Inc. Mutual Fund 2026/Q3 +681,633 0.1%
First Trust Advisors L.P. Mutual Fund 2026/Q3 +510,056 0.6%
TD Asset Management Mutual Fund 2026/Q3 +432,400 0.1%
Voya Investment Management LLC Mutual Fund 2026/Q3 +253,455 0.1%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +454,596 0.1%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
2 Nov 2026 Blake Borgeson Independent Director Open Market Disposition -40,000 $3.88 5,979,863
1 Nov 2026 Fred Hassan Chair of the Board Other Acquisition +156,658 – 156,658
5 Oct 2026 Robert Hershberg Independent Director Derivative Exercise and Sale -25,000 $5.00 73,732
5 Oct 2026 Blake Borgeson Independent Director Automatic Disposition -50,000 $4.84 6,019,863
30 Sep 2026 Dean Li Director Other Acquisition +3,378 – 3,231,331
30 Sep 2026 Zavain Dar Independent Director Other Acquisition +4,607 – 156,947
14 Sep 2026 Ben Taylor CFO & President of Recursion UK Sale to Issuer -5,396 $3.41 325,957
7 Sep 2026 Najat Khan Chief Executive Officer Automatic Disposition -22,408 $3.52 159,729
31 Aug 2026 Blake Borgeson Independent Director Automatic Disposition -30,000 $3.34 6,069,863
20 Aug 2026 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -77,290 $3.39 –
19 Aug 2026 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -75,000 $3.40 –
18 Aug 2026 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -100,000 $3.28 –
17 Aug 2026 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -26,806 $3.00 –
16 Aug 2026 Ben Taylor CFO & President of Recursion UK Sale to Issuer -25,018 $3.16 319,874
16 Aug 2026 David Hallett Chief Scientific Officer Sale to Issuer -26,657 $3.16 430,508
16 Aug 2026 Najat Khan Chief Executive Officer Sale to Issuer -80,498 $3.16 182,137
12 Aug 2026 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -100,000 $3.31 –
11 Aug 2026 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -50,000 $3.37 –
9 Aug 2026 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -100,000 $3.27 –
6 Aug 2026 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -100,000 $3.25 –

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 142,265,985 23.8% 6.1
15 Oct 2026 161,926,247 30.2% 4.4
30 Sep 2026 157,938,412 29.5% 6.1
15 Sep 2026 178,724,433 33.4% 12.6
31 Aug 2026 179,145,796 33.5% 10.6
14 Aug 2026 177,923,359 33.2% 13.4

Discussion

No comments yet — be the first to weigh in on RXRX.

Sign in to join the discussion.

Scroll to Top